YOLFTbeta
Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals Holding

CRBP · NASDAQ · Healthcare / Biotechnology

3.39USD-0.02 (-0.59%)

Price History

Full chart

Market Stats

Previous Close3.41
Open3.38
Day Range3.27 – 3.53
52-Week Range6.33 – 20.56
Volume566.21K
Market Cap144.09M
P/E (TTM)0.00
Forward P/E0.00
EPS-5.88
Dividend Yield0.00%
Beta2.64
50-Day Avg9.41
200-Day Avg9.07

About

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Yuval Cohen Ph.D.
  • Employees36
  • Headquarters500 River Ridge Drive, Norwood, MA, United States, 02062, USA
  • Websitehttps://www.corbuspharma.com

Leadership

  • Dr. Yuval Cohen Ph.D.CEO & Director · b. 1975
  • Mr. Sean F. Moran CPA, M.B.A.Chief Financial Officer · b. 1958
  • Dr. Ian Hodgson B.Sc., Ph.D.Chief Operating Officer · b. 1973
  • Mr. G. Scott Goeken J.D., M.S.General Counsel & Corporate Secretary
  • Ms. Christina Bertsch M.A.Vice President of Human Resources
  • Mr. Nishant C. SaxenaChief Business Officer
  • Dr. Leonardo Viana Nicacio M.D.Chief Medical Officer · b. 1978

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0648.38K1.91M2.44M4.82M36.14M3.94M881.71K0000
Growth (%)----+194.80%+27.66%+97.62%+649.51%-89.11%-77.61%-100.00%---
Cost of Revenue--1.26M5.89M15.44M26.04M48.61M89.60M98.27K1.64M1.49M31.17M600.00K233.00K
Gross Profit---1.26M-5.24M-13.53M-23.60M-43.79M-53.46M3.94M-757.53K-1.49M-31.17M-600.00K-233.00K
Gross Margin----808.21%-707.60%-967.09%-908.11%-147.91%100.00%-85.92%----
Operating Expense--1.39M3.61M6.46M8.96M12.96M23.64M126.75M55.23M33.35M13.91M48.12M85.08M
Operating Income-824.15-557.28K-2.65M-8.85M-19.99M-32.56M-56.75M-77.10M-122.81M-55.99M-34.84M-45.08M-48.72M-85.31M
Operating Margin----1365.51%-1045.56%-1334.43%-1176.78%-213.33%-3119.20%-6350.09%----
EBITDA-62.82-556.52K-2.64M-8.81M-19.90M-32.31M-56.25M-76.37M-121.12M-42.17M-38.73M-40.10M-37.74M-78.30M
EBITDA Margin----1358.73%-1040.97%-1323.96%-1166.54%-211.28%-3076.17%-4782.86%----
Net Income-886.96-602.35K-2.54M-8.85M-20.00M-32.42M-55.67M-71.45M-111.27M-45.55M-55.83M-44.60M-40.21M-78.54M
Net Income Margin----1365.05%-1046.27%-1328.65%-1154.48%-197.69%-2826.08%-5166.42%----
R&D575.09210.67K1.26M5.89M15.44M26.04M48.61M89.60M98.27M36.45M16.14M31.17M32.22M70.09M
R&D as % of Total Revenue---908.21%807.60%1067.09%1008.11%247.91%2495.85%4133.50%----
Interest Expense-45.11K24.02K2.44K0183.11K019.02K1.03M1.83M2.13M2.92M1.87M0
Interest Expense % of Total Revenue---0.38%0.00%7.50%0.00%0.05%26.12%207.61%----

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets544.98305.52K6.60M12.88M17.89M66.98M46.99M49.14M102.29M107.73M66.31M28.27M155.88M168.19M
Total Liabilities743.362.09M738.04K3.89M8.97M9.19M19.47M42.98M57.02M38.62M33.32M35.18M13.45M20.69M
Total Equity-198.38-1.78M5.86M8.99M8.92M57.78M27.52M6.16M45.27M69.11M32.99M-6.91M142.43M147.50M
Cash542.48303.02K6.26M12.34M14.99M62.54M41.75M31.75M85.43M25.01M17.00M13.72M17.20M28.49M
Total Debt-638.08K144.39K162.02K276.39K332.86K394.31K9.45M26.84M26.59M25.09M20.89M3.24M1.63M
Net Debt-542.48335.06K-6.12M-12.18M-14.72M-62.20M-41.35M-22.30M-58.60M1.58M8.09M7.16M-13.96M-26.86M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-769.73-366.71K-2.36M-4.65M-13.57M-27.80M-30.07M-45.72M-99.69M-48.18M-37.54M-36.10B-41.79M-64.49M
Investing Cash Flow---64.45K-114.04K-353.03K-707.43K-2.30M-2.74M-484.49K-73.42M30.07M35.64B-121.31M-1.64M
Financing Cash Flow1.04K127.25K8.39M10.84M16.74M76.01M11.42M38.46M154.87M60.82M-533.62K-2.82B166.58M77.43M
Capital Expenditure0064.45K114.04K353.03K707.43K2.30M2.74M484.49K54.17K13.45K307.00K
Free Cash Flow-769.73-366.71K-2.43M-4.76M-13.92M-28.50M-32.37M-48.46M-100.17M-48.24M-37.56M-36.10B-41.79M-64.50M
Dividends Paid--0000--------
FCF to OCF100.00%100.00%102.73%102.45%102.60%102.55%107.65%106.00%100.49%100.11%100.04%100.00%100.00%100.01%
Dividend Paid to FCF--0.00%0.00%0.00%0.00%--------

Earnings

Report DateFeb 10, 2015May 13, 2015Aug 13, 2015Nov 10, 2015Mar 28, 2016May 13, 2016Aug 12, 2016Nov 10, 2016Mar 8, 2017May 9, 2017Aug 9, 2017Nov 8, 2017Mar 12, 2018May 10, 2018Aug 8, 2018Nov 8, 2018Mar 12, 2019May 9, 2019Aug 8, 2019Nov 7, 2019Mar 12, 2020May 11, 2020Aug 6, 2020Nov 9, 2020Mar 15, 2021May 13, 2021Aug 12, 2021Nov 12, 2021Mar 8, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 7, 2023May 9, 2023Aug 8, 2023Nov 7, 2023Mar 12, 2024May 7, 2024Aug 6, 2024Nov 7, 2024Mar 10, 2025May 6, 2025Aug 5, 2025Nov 12, 2025Mar 9, 2026May 12, 2026Aug 6, 2026Nov 11, 2026
EPS Estimate-0.90-1.50-1.80-2.40-1.90-2.40-2.25-3.30-4.10-4.80-5.60-4.80-4.62-4.10-6.45-6.65-7.80-4.45-10.68-10.90-10.74-12.70-11.25-12.18-7.56-4.80-3.75-3.30-3.22-2.55-1.80-1.65-2.10-4.09-3.10-2.06-2.36-1.09-1.19-0.95-1.26-1.07-1.33-1.71-1.58-1.22-1.30-1.45
EPS Actual-1.80-1.80-3.00-1.80-1.80-2.40-3.30-3.60-5.40-4.80-4.50-4.20-6.30-6.30-6.30-7.80-9.00-12.900.90-9.60-12.30-12.90-15.60-12.90-3.00-4.20-4.50-0.60-2.40-2.40-3.30-2.10-2.61-4.24-2.05-2.27-1.81-0.83-0.90-1.15-0.78-1.39-1.44-1.90-1.25-1.23-1.81-
Surprise-100.00%-20.00%-66.67%25.00%5.26%0.00%-46.67%-9.09%-31.71%0.00%19.64%12.50%-36.36%-53.66%2.33%-17.29%-15.38%-189.89%108.43%11.93%-14.53%-1.57%-38.67%-5.91%60.32%12.50%-20.00%81.82%25.47%5.88%-83.33%-27.27%-24.29%-3.67%33.87%-10.19%23.31%23.85%24.37%-21.05%38.04%-29.91%-8.27%-11.11%20.69%-0.82%-39.23%-
TimingPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap144.09M
Enterprise Value26.74M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales169.88
Price / Book1.37
EPS-5.88
Book Value5.48
Revenue (TTM)0
Gross Profit (TTM)-90.26M
EBITDA-106.68M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-95.58%
Return on Assets-53.00%
Shares Outstanding19.34M
Shares Float15.16M
Beta2.64
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 10 analystsTarget 34.03
  • Strong Buy
    7
  • Buy
    3

Ownership Breakdown

Institutions
73.94%
Insiders
1.24%
Retail / Other
24.82%

Top Institutional Holders

  • Cormorant Asset Management, LLC
    2.34M12.12%
  • Orbimed Advisors LLC
    1.74M8.98%
  • Aberdeen Group PLC
    1.32M6.83%
  • Vanguard Capital Management, LLC
    734.11K3.80%
  • Jones Hill Capital LP
    653.57K3.38%
  • Prosight Management, LP
    650.00K3.36%
  • Stonepine Capital Management Llc
    383.46K1.98%
  • Armistice Capital, LLC
    364.00K1.88%
  • Renaissance Technologies Corp
    347.00K1.79%
  • Susquehanna International Group, LLP
    333.42K1.72%
  • ADAR1 Capital Management LLC
    331.78K1.72%
  • Diadema Partners LP
    301.26K1.56%
  • BlackRock Inc
    271.64K1.40%
  • Dimensional Fund Advisors, Inc.
    190.21K0.98%
  • Geode Capital Management, LLC
    187.03K0.97%

Top Fund Holders

  • Biotech Growth Ord
    538.60K2.78%
  • Vanguard MStar Total Stk Mkt Idx Invest
    533.58K2.76%
  • abrdn Healthcare Investors
    434.03K2.24%
  • iShares Russell 2000 ETF
    400.82K2.07%
  • abrdn Life Sciences Investors
    385.28K1.99%

Stock Splits

  • Feb 14, 20231:30